[go: up one dir, main page]

WO2015032973A1 - Compositions d'érythropoiétine pour une administration orale - Google Patents

Compositions d'érythropoiétine pour une administration orale Download PDF

Info

Publication number
WO2015032973A1
WO2015032973A1 PCT/EP2014/069183 EP2014069183W WO2015032973A1 WO 2015032973 A1 WO2015032973 A1 WO 2015032973A1 EP 2014069183 W EP2014069183 W EP 2014069183W WO 2015032973 A1 WO2015032973 A1 WO 2015032973A1
Authority
WO
WIPO (PCT)
Prior art keywords
epo
pharmaceutical composition
cymal
cyclohexyl
maltoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/069183
Other languages
English (en)
Inventor
Mateja Cegnar
Barbara Podobnik
Simon CASERMAN
Miha Homar
Janez Kerc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals dd filed Critical Lek Pharmaceuticals dd
Publication of WO2015032973A1 publication Critical patent/WO2015032973A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin

Definitions

  • the present invention relates to compositions comprising erythropoietin, one or more absorption enhancers and/or one or more bioadhesive polymers for oral administration.
  • Erythropoietin is a glycoprotein hormone, which is mainly produced in the kidney, but also to a certain extent in the liver. It controls erythropoiesis (red blood cell production) and acts as a cytokine for erythrocyte (red blood cell) precursors in the bone marrow. EPO exerts its biological effect of stimulating the proliferation and differentiation of erythroid progenitors by binding to specific cell-surface receptors, i.e., erythropoietin receptors (EPO-Rs) that are most abundant on erythroid progenitors located primarily in the bone marrow. EPO-Rs are also located in non- hematopoietic tissues where they mediate other biological functions.
  • EPO-Rs erythropoietin receptors
  • EPO increases hemoglobin serum levels thus reducing the need for blood transfusion. It is used in the treatment of anemia, for example resulting from chronic kidney disease and
  • myelodysplasia from cancer therapy (for example chemotherapy and/or radiation), as well as from other critical illnesses (for example heart failure).
  • cancer therapy for example chemotherapy and/or radiation
  • other critical illnesses for example heart failure
  • EPO can be produced biosynthetically using recombinant DNA technology.
  • the recombinant human EPO (rhEPO) dosage form currently available on the market is a ready for injection liquid vial (syringe), which is usually administered 2-3 times weekly.
  • rhEPO recombinant human EPO
  • cumulative doses are required that significantly exceed levels of endogenous EPO.
  • serum levels result in prolonged circulation times of EPO and unspecific binding to non-targeted tissue, which may lead to undesired side effects.
  • ESAs shortened overall survival and/or increased the risk of tumor progression or reoccurrence in some clinical trials in patients with breast, non-small cell lung, head and neck, lymphoid and cervical cancers. Severe side effects have been recently reported in chemotherapy and/or radiation receiving cancer patients taking anti-anemia drugs. These side effects, i.e., increased risk of death and tumor growth, were attributed to the high serum levels of parenterally administered EPO, which enable EPO to act on other non-target (undesired) tissues.
  • parenteral administration as practiced with the current EPO dosage forms on the market, is also inconvenient for patients, especially in case of chronic therapies. Apart from the inconvenience for the patients, parenteral delivery systems are also more expensive in terms of production and drug administration through health care professionals.
  • the peroral route would be the most convenient. It is also contemplated that the peroral delivery of EPO would benefit from entering the systemic circulation via the portal vein, which would more closely resemble the physiological pathway of endogenous EPO that is produced in the liver.
  • the present invention overcomes the aforesaid problems by providing a pharmaceutical composition of EPO suitable for oral administration.
  • Figure 1 Relative number of reticulocytes in rats after subcutaneous administration of EPO (Study code P44).
  • Figure 2 Relative number of reticulocytes (% erythrocytes) in rats after peroral administration of EPO- and mC6EPO-loaded nanoparticles (EPO-NPs and mC6EPO-NPs) and placebo (demi water) (Study code P51 ).
  • FIG. 3 Relative number of reticulocytes in rats after intrajejunal administration of EPO formulation (EPO-loaded nanoparticles, NPs-EPO-D'”) and placebo (empty nanoparticles) (Study code P55).
  • the present invention provides pharmaceutical compositions comprising erythropoietin (EPO) as defined herein, one or more absorption enhancers selected from the group of "CYMALs” and “PMALs” as defined herein, and/or one or more bioadhesive polymers.
  • EPO erythropoietin
  • Such pharmaceutical compositions may be obtained by mixing appropriate solutions of EPO and the one or more other components of the pharmaceutical composition at an appropriate pH, optionally followed by, for instance, freeze drying.
  • the appropriate pH for preparing the inventive pharmaceutical compositions will generally be maintained in a buffered solution and adjusted to maintain the biological activity of the erythropoietin and to ensure good association of the different components.
  • EPO refers to erythropoietin and may be a natural or recombinant EPO, recombinant human EPO (rhEPO), or any protein or peptide having in vivo biological activity of the EPO glycoprotein, e.g., a wild type or mutant EPO, an EPO peptidomimetic, an EPO fragment, or an EPO conjugate as provided herein.
  • the species from which EPO is derived can be animal, mammal or human species. Human EPO is, however, preferred.
  • Human EPO comprises the known human erythropoietin having 165 amino acids after posttranslational cleavage of the N-terminal signal peptide of 27 amino acids and the C-terminal arginine. It further comprises human EPO in it's naturally glycosylated state, i.e., including all carbohydrate side chains.
  • the abbreviation "P" as used herein stands for EPO as defined above.
  • the invention provides novel EPO conjugates, wherein one or more lipophilic side chain(s) are attached to erythropoietin.
  • the one or more lipophilic side chain(s) may be attached to the o amino group of the N-terminal amino acid and/or to the ⁇ -amino group of lysine residues present on the EPO amino-acid seguence, e.g., via an amide bond.
  • Each of the one or more lipophilic side chain(s) attached to the EPO comprises one or more moieties "B” and/or a branched or straight chain alkylene moiety -(CH 2 ) m - ⁇ While each of the one or more lipophilic side chain(s) attached to the EPO may comprise up to 6 moieties "B", it is egually preferred that each of the one or more lipophilic side chain(s) attached to the EPO comprises only one moiety "B".
  • the moiety B is a bivalent aromatic moiety selected from arylene or heteroarylene.
  • arylene refers to a bivalent aromatic moiety comprising 4, 5, 6 or 7 ring carbon atoms.
  • heteroarylene refers to an arylene group comprising 1 , 2, 3 or 4 hetero-ring atoms selected from oxygen, nitrogen, and sulfur.
  • the arylene or heteroarylene moiety may, each and independently, be unsubstituted, or may be substituted with one or two substituents each independently selected from straight chain or branched Ci_ 4 -alkyl, -OH, -SH, -NH 2 , -CHO, and - COOH.
  • the alkylene moiety -(CH 2 ) m - is a branched or straight chain alkylene moiety having 4 to 20 carbon atoms, or from 5 to 11 carbon atoms, or having 5, 7, 9 or 11 carbon atoms (i.e., m is an integer from 4 to 20, or from 5 to 11 , or m is 5, 7, 9 or 11 ).
  • the lipophilic side chain(s) may further comprise a polar end group Y and/or one or more linker(s) each independently selected from the group consisting of L and X.
  • the linker X is selected from -CH 2 NH-, -NHCO-, -CONH-, -COO-, -SS-, -S-CH 2 - and -NN-;
  • the polar end group Y is a polar group selected from -COOH, -CHO and -COOCH 3 . While it is preferred that a polar group Y is present in the EPO conjugates of the invention, it is egually preferred that no polar group Y is present therein.
  • the number of lipophilic side chains attached to EPO ranges from 1 to 6, for example, 1 , 2, 3, 4, 5 or 6 side chains may be present in the EPO conjugates according to the invention. If more than one lipophilic side chains are present in the EPO conjugates of the invention, e.g., if 2 or more side chains are present, these lipophilic side chains may either be the same or different.
  • the one or more lipophilic side chain(s) attached to the EPO comprise(s) one or more of a bivalent aromatic moiety B, wherein B is arylene. Said arylene moiety may have 4, 5, 6 or 7 ring carbon atoms.
  • Said arylene moiety is either unsubstituted, or is substituted with one or two substituents each independently selected from -CH 3 , -OH, -SH, -NH 2 , -CHO, and -COOH.
  • the substituent -CH 3 is preferred.
  • B is a phenylene, toluylene, or xylene moiety. More preferably, B is an o-, m- or p-phenylene moiety, most preferably a p-phenylene moiety.
  • the one or more lipophilic side chain(s) attached to the EPO comprise(s) one or more of a bivalent aromatic moiety B and/or a branched or straight chain alkylene moiety -(CH 2 )m-, and further one or more linker(s) each independently selected from the group consisting of L and X, and/or a polar end group Y, wherein
  • L represents -NHCO-
  • B represents an arylene group having 6 carbon atoms, and is preferably a p-phenylene group
  • X represents -CH 2 NH-
  • n is an integer from 4 to 20, or from 5 to 11 , or is 5, 7, 9 or 11 ;
  • Y is selected from -COOH, -CHO, and -COOCH 3 ; preferably Y is -COOH.
  • EPO conjugates of the present invention are represented by the following formula
  • P EPO
  • L represents a covalent linkage between P and B, and is selected from -NHCO-, -NHCH 2 - more preferably L represents -NHCO-;
  • B represents a hetero- or homo-bifunctional linker, enabling attachment of the lipophilic moiety to the protein.
  • B represents a bivalent aromatic moiety, preferably an arylene or heteroarylene moiety with 4, 5, 6 or 7 ring carbon atoms, more preferably 6 carbon atoms, and optionally, one oxygen, nitrogen, or sulfur ring atom, which arylene or heteroarylene group may be unsubstituted or substituted with one or two groups selected from straight chain or branched d-4-alkyl, -OH, -SH, -NH 2 , -CHO, -COOH.
  • heteroarylene group is methyl.
  • B represents a phenylene, toluylene, xylene or pyridylene group. More preferably, B is an o-, m- or p-phenylene group, most preferably a p-phenylene group;
  • X represents a covalent linkage between B and the lipophilic moiety, wherein X is either -CH 2 NH-, -NHCO-, -CONH-, -COO-, -SS-, -S-CH 2 - or -NN-, preferably X represents -CH 2 NH-, -NHCO-, or -CONH-, more preferably X represents -CH 2 NH-;
  • (CH 2 )m represents a branched or straight chain alkylene moiety having 4 to 20 carbon atoms, or from 5 to 11 carbon atoms, or having 5, 7, 9 or 11 carbon atoms (i.e., m is an integer from 4 to 20, or from 5 to 11 , or m is 5, 7, 9 or 11 );
  • Y represents a polar group selected from -COOH, -CHO, and -COOCH 3 .
  • Y is - COOH;
  • n represents the number of lipophilic side chains attached to EPO, preferably attached via an amide bond to the oamino group of the N-terminal amino acid and/or to the ⁇ -amino group of lysine residues present on the EPO amino-acid sequence, n may be selected from 1 to 6.
  • n is 2 or 3.
  • the values for n equal to 2 or 3 are preferred for fine tuning the lipophilicity.
  • the EPO conjugate has the general formula P[(L)-B-(X)-(CH 2 ) m -Y] n ,
  • P EPO
  • L, B, X, m and Y are defined as in any one of the above embodiments, and
  • n represents the number of lipophilic side chains attached to EPO and ranges from 1 to 6.
  • the lipophilic side chain [(L)-B-(X)-(CH 2 ) m -Y] may be attached via an amide bond to the oamino group of the N-terminal amino acid and/or to the ⁇ -amino group of lysine residues present on the EPO amino-acid sequence.
  • EPO conjugates are represented by the following formulas:
  • sequence of the structural elements according to any of the above formulas is preferred as allows an attachment of the one or more lipophilic side chain(s) to the oamino group of the N-terminal amino acid and/or to the ⁇ -amino group of lysine residue present on the EPO amino-acid sequence, e.g., via an amide bond, and via an aromatic moiety B to the linker X.
  • the partial group -(CH 2 ) m -Y can be introduced, e.g., by a ⁇ -amino carboxylic acid.
  • the lipophilic side chains comprise the structural elements in the order given in the above formulas
  • the parameters as defined above i.e., L, B, X, -(CH 2 ) m -, n and Y
  • L, B, X, -(CH 2 ) m -, n and Y are independent of each other and can be selected and combined freely. If they occur repeatedly within one molecule, for example in the case that more than one side chains are present per molecule erythropoietin, e.g., if n is 2 or more, the parameters may be different in each side chain.
  • the bivalent linker parameters L, B and X may be present in the orientation as depicted in the above formulas, but also in reversed orientation.
  • the lipophilic side chain(s) of the EPO conjugates as defined above typically comprises one bivalent aromatic moiety B.
  • more than one bivalent aromatic moieties B may be present as well, e.g., 2, 3, 4, 5 or 6 bivalent aromatic moieties B may be present.
  • the covalent linkage(s) L and/or X in the lipophilic side chain of the EPO conjugate as defined above may be present or omitted.
  • EPO erythropoietin
  • the term erythropoietin, or abbreviated EPO comprises any natural or recombinant EPO, recombinant human EPO (rhEPO), or any protein or peptide having in vivo biological activity of EPO glycoprotein, i.e. wild type or mutant EPO, EPO peptidomimetic, or EPO fragment.
  • the species from which the EPO is derived comprise animal, mammal or human species, especially human EPO.
  • Human EPO comprises the known human erythropoietin having 165 amino acids after posttranslational cleavage of the N-terminal signal peptide of 27 amino acids and the C-terminal arginine. It may further comprise the human erythropoietin in the naturally glycosylated state, i.e. including all carbohydrate side chains.
  • P is preferably a human recombinant EPO (rhEPO).
  • n the lipophilic side chains
  • the present EPO conjugates In comparison with unmodified EPO, the present EPO conjugates have an increased permeability across the intestinal membrane. Therefore, the present EPO conjugates are particularly suited for peroral administration and/or for the development of advanced oral drug delivery systems. Preparation of the EPO conjugates
  • the present invention further provides a process for the production of the EPO conjugates according to the present invention.
  • the process for the preparation of the EPO conjugates, wherein the one or more lipophilic side chain(s) are attached to 1 to 6 oamino group(s) of the N-terminal amino acid and/or to the ⁇ -amino group(s) of lysine residue present on the EPO provided herein generally comprises four steps: (1 ) modification (conversion) of a primary amine of the EPO into an amid linker and simultaneous introduction of an aldehyde group, (2) conjugation to an amino fatty acid and reductive amination, (3) gel filtration, (4) concentration and sterile filtration.
  • the first reaction step involves protein modification, wherein one or more bifunctional linker moieties B are attached to 1 to 6 oamino group(s) of the N-terminal amino acid and/or to the ⁇ -amino group(s) of lysine residue present on the EPO amino-acid sequence via reaction of EPO with a reagent comprising the aromatic moiety B substituted with an N-hydroxysuccinimidyl ester functional group (also referred to as NHS activated ester of B), and an aldehyde functional group.
  • B has the same meaning as defined in any of the above embodiments.
  • the N- hydroxysuccinimidyl ester reacts in an acylation reaction with the amino group of the EPO in that the N-hydroxysuccinimide serves as leaving group and the carbonyl group of the former NHS ester forms an amide bond with the amino group of the protein.
  • the intermediate product of this step can be formulated as:
  • the aromatic moiety B is a phenylene moiety.
  • the specific reagent employed in this reaction step is N-hydroxysuccinimidyl 4-formylbenzoate (SFB).
  • the respective reagent may be used in equimolar amounts, it is preferred that the reagent is used in excess amounts over EPO.
  • the molar excess ratio of linker /EPO is from 1 to 100, or from 6 to 36, preferably 6 molecules of linker per molecule EPO.
  • the molar excess ratio of SFB/EPO is from 6 to 36.
  • Preferably 6 molecules SFB per molecule EPO are used.
  • the aldehyde function is condensed with the amino function of a ⁇ -amino carboxylic acid to the corresponding Schiff's base.
  • the ⁇ -amino carboxylic acids may comprise 4 to 20 methylene groups: HOOC-(CH 2 )4-2o-NH 2 , preferably from 4 to 12 methylene groups.
  • the ⁇ -amino carboxylic acid may be used in equimolar amounts, it is preferred that the ⁇ -amino carboxylic acid is used in excess amounts over EPO.
  • the molar excess ratio of SFB/EPO may be from 30 to 120, or from 30 to 90.
  • 60 molecules of ⁇ -amino carboxylic acid per molecule EPO are used.
  • the intermediate product of this step can be formulated as:
  • a reducing agent known to the skilled artisan.
  • complex alkali borohydrides such as sodium cyanoborohydride (Na[CN-BH 3 ]) may be used.
  • the final product can be formulated as:
  • the Schiff base intermediate may be isolated before performing the reduction step. It is, however, not necessary to isolate the Schiff base intermediate. Rather, the Schiff base intermediate can be processed further directly into the final product (i.e., reduction to the final EPO conjugate as defined above). Hence, the condensation and reducing reactions can be effected in a "one pot" manner.
  • the final reaction mixture can be purified by separating by-products, such as non-reacted EPO, e.g., rhEPO, or excess reagents such as SFB and ⁇ -aminocarboxylic acid, from the desired conjugated EPO product.
  • Suitable purification techniques are known to one skilled in the art, such as column chromatography, or size exclusion chromatography with a gel ("gel filtration").
  • a Superdex75 PrepGrade (XK 26/60) column from Sigma/Aldrich may be used for purification by gel filtration.
  • the fractions containing the desired conjugated EPO can be collected, concentrated, for example by ultrafiltration, and filtrated with a sterile filter into a sterile state.
  • CYMALs cycloalkylglycosides
  • CYMALs cycloalkylmaltosides
  • the carbohydrate component is linked by an O-glycosidic bond at the "free end" of maltose (carbon atom number 1 ) to an alkyl chain, wherein the alkyl chain comprises at the most distal position of the alkyl chain, the so called ⁇ -position, a cycloalkyl group.
  • the preferred disaccharide is maltose; the preferred alkyl chain comprises 1 to 7 methylene groups, i.e. (CH 2 )i-7, and the cycloalkyl rest at the ⁇ -position is a cyclohexyl group.
  • Preferred "CYMALs” are, however, CYMAL®-5,
  • a further group of preferred absorption enhancers are amphiphilic polymers referred to herein as "PMALs" having a highly charged cationic and anionic backbone to which an aliphatic tail is attached.
  • the expression “PMAL” describes alternant polymers prepared by the monomers of maleic acid anhydride and an oolefine having 6, 8, 10, 12, 14, 16 or 18 carbon atoms, respectively (i.e., "poly(maleic acid anhydride-alt-oolefine"), which are grafted with
  • dimethylamino propylamine side chains may be prepared by reaction of poly(maleic acid anhydride-alt-oolefine) with 3-dimethylamino propylamine, whereby the anhydride group reacts with the primary amino function of the 3-dimethylamino propylamine to form an amide bond.
  • the "non-reacting" or leaving carboxylic acid function of the original anhydride function is present as a free carboxylic acid, and simultaneously, the basic dimethylamino function is present in the side chain.
  • a zwitterionic or ampholytic polymer (“amphipol") is obtained.
  • Suitable bioadhesive polymers to be used in the pharmaceutical compositions of the invention are selected from polyacrylic acid, polymethyl vinyl ether/maleic acid anhydride, acid-resistant enteric polymers, basic and acidic polysaccharides and polyesters.
  • Other polymers include cationic natural polymers such as chitosan and its derivatives (e.g. trimethylchitosan, PEG- chitosan), gelatin type A etc. and anionic polysaccharides, glycosaminoglycans, polyaminoacids and various copolymers (e.g.
  • bioadhesive polymers are chitosan (CS) and its derivatives, e.g. trimethylchitosan (TMC), alginic acid, its derivatives and salts, as well as combinations thereof.
  • bioadhesive polymers have the advantage that they are generally non-toxic and not irritating to the mucosa and do not require organic solvents, which would not be desirable from the point of protein stability and adverse effects on the patient. They may be added to the pharmaceutical compositions of the invention to form nanoparticles providing partial protection against protein degradation, and to enhance the mucoadhesivness to localize the delivery system closer to the intestinal wall.
  • CS and its derivatives such as TMC have a dual effect, and also act as absorption enhancing agents as a part of the polymer carrier.
  • one or more additional absorption enhancing agent e.g., as defined above
  • no other absorption enhancing agents are comprised in the pharmaceutical compositions of the present invention in this case.
  • Nanoparticle formation is based on self-association of the ingredients in aqueous media under mild stirring conditions.
  • the formation of nanoparticles or polyelectrolyte complexes can be obtained or assisted by ionotropic gelation and/or polyelectrolyte complexation using counter ions and/or polymers, for example polyphosphates such as tripolyphosphate (tpp) or polyionic polymers.
  • This process does not require the use of organic solvents, toxic ingredients or covalent crosslinking agents and also does not employ harsh processing conditions. Therefore, the biological activity of the sensitive protein drug is preserved.
  • the method also does not face technical and economical hurdles, therefore it is suitable for industrial scale production.
  • the pharmaceutical composition comprises EPO as defined herein, and one or more absorption enhancers selected from the group consisting of CYMAL®-5, CYMAL®-6 and CYMAL®-7.
  • the absorption enhancer is CYMAL®-7.
  • a bioadhesive polymer may further be present in the pharmaceutical compositions according to this embodiment.
  • the bioadhesive polymer is either chitosan (CS), or trimethylchitosan (TMC), or a combination thereof. More preferably, the bioadhesive polymer is chitosan (CS).
  • the absorption enhancer is PMAL-C10®.
  • the pharmaceutical composition is present in the form of a nanocomplex of EPO as defined herein and the one or more amphiphilic polymers. These nanocomplexes have a size in the range of from about 10 nm to about 300 nm, preferably from about 10 nm to about 100 nm, most preferably from about 10 nm to about 30 nm with a low polydispersity.
  • a bioadhesive polymer may further be present in the pharmaceutical compositions according to this embodiment.
  • the bioadhesive polymer is either chitosan (CS), or
  • the bioadhesive polymer is a combination of chitosan (CS) and trimethylchitosan (TMC). If a combination of chitosan (CS) and trimethylchitosan (TMC) is used, CS and TMC are used at a ratio CS to TMC of, e.g., 1 to 0.2.
  • the pharmaceutical composition comprises EPO as defined herein, and a bioadhesive polymer.
  • the bioadhesive polymer is chitosan (CS) or trimethylchitosan (TMC), or a combination thereof.
  • the ratio of CS/TMC is between 1 :0.01 to 1 : 10, e.g., 1 :0.1 , or 1 :0.2, or 1 :0.3, or 1 :0.4, or 1 :0.5, or 1 :1 , or 1 :3.
  • the pharmaceutical composition is present in the form of nanoparticles, obtained by a process of particle formation of CS or TMC, or of TMC and CS, together with EPO as defined herein. These nanoparticles have a uniform particle size in the range of from 100 nm to 400 nm and also a low polydispersity.
  • compositions according to this embodiment of the invention may comprise an additional absorption enhancing agent as defined herein, however, it is equally preferred that the pharmaceutical compositions according to this embodiment of the invention do not comprise an additional absorption enhancing agent.
  • compositions according to the invention may further comprise
  • Tpp triphenylphosphate
  • compositions of the invention are in the form of
  • nanoparticles/nanocomplexes It is preferred that the particle size of the
  • nanoparticles/nanocomplexes is less than 4000 nm, or less than 1000 nm, or less than 500 nm, or less than 400 nm, allowing the skilled person to select the particle size to fulfil the needs and ease of preparation for instance.
  • smaller particle sizes may be preferred for a good distribution of the drug in the gastrointestinal tract and adhesion to the mucosa without an excess concentration at a specific location.
  • the nanoparticle size should be less than about 4000 nanometers, preferably less than about 1000 nanometers, more preferably less than about 500 nanometers, and most preferably less than about 400 nanometers. Nanoparticles from 300 to 400 nanometers are particularly preferred. However, larger particle sizes may be preferred when a higher drug load is desired or required.
  • the nanosize pharmaceutical compositions of EPO provided herein have high oral bioavailability and efficacy.
  • a particular advantage of the oral pharmaceutical compositions provided herein lays in the closer resemblance to endogenous EPO entering the systemic circulation via the portal vein.
  • Endogenous EPO is produced by the peritubular capillary endothelial cells in the kidney and liver.
  • the liver accounts for 10-20% of EPO production and the liver can naturally regulate EPO plasma levels.
  • Enteral absorption of EPO results in better regulation of hormone levels by feed back regulation mechanisms in the liver, thereby preventing peak concentrations of the drug that are responsible for the undesired side effects. This regulation is not efficient upon peripheral administration of EPO.
  • the pharmaceutical compositions of the present invention achieve plasma concentrations of EPO, which are lower than in case of parenteral administration, but higher as in untreated case.
  • one of the benefits of the pharmaceutical compositions of the invention is the reduction of severe side effects in comparison to parenterally administered EPO of the current commercial preparation.
  • the invention further provides the pharmaceutical compositions as defined herein for use in the treatment of anemia, for example resulting from chronic kidney disease and myelodysplasia, from the treatment of cancer, for example by chemotherapy and/or radiation, and from other critical illnesses, for example heart failure.
  • the pharmaceutical compositions according to the present invention are further intended for use in the treatment of a disorder related to a reduction of red blood cells, particularly for use in the treatment of a disorder related to a reduction of red blood cells, wherein the risk of side effects caused by abnormally high EPO levels is increased.
  • Human colon carcinoma cell line Caco-2 cultured on permeable supports, were used to determine the permeability coefficient of EPO or its conjugate in different formulations (i.e., in nanocomplexes and nanoparticles).
  • Caco-2 cells were seeded on tissue-culture-treated polyester filters (growth area 1.12 cm 2 , membrane pore size 0.4 ⁇ ) in Transwell 12 wells per plates (Costar 3460) at a seeding density of 100.000 cells/well.
  • DMEM SIGMA, D5921 ;
  • Dulbecco's modified Eagle's medium supplemented with 10% HIFBS (heat inactivated fetal bovine serum), 1 % glutamine and 1 % antibiotic-antimycotic solution was used as culture medium, and added to both the donor and acceptor compartments. The medium was replaced every 48 hours. The cultures were kept in an atmosphere of 95% air and 5% C0 2 at 37°C. Transport experiments were performed 21 days after the seeding.
  • HIFBS heat inactivated fetal bovine serum
  • TEER values transepithelial electrical resistance of the Caco-2 cell monolayers were monitored with a Millicell RTM-Electrical Resistance System (Millipore Corp.) connected to a pair of chopstick electrodes.
  • DMEM pre-warmed transport media
  • the cells were incubated for 3 hours with 0.5 ml transport media containing testing formulation.
  • ELISA protein analysis
  • the TEER value which is a good indicator of Caco-2 cell monolayer integrity, was measured before and after the transport experiment (3h), and also after 24h in the culture media to study the reversibility of the effect of the testing formulations on Caco-2 cell monolayer.
  • the permeability coefficient was calculated only for those testing molecules where the TEER value of the cells was not affected, or showed a gradual recovery over time to the initial TEER value.
  • Test items and placebo were administered perorally or intrajejunally only once (at day 0 of the study). Blood samples were taken every second day throughout the 14 day lasting study. Blood samples were collected from the terminal vein (40 ⁇ ) into the pipette and immediately diluted with Cellpack reagent, Sysmex (160 ⁇ , 1/5, v/v) in Eppendorf 0.5 ml tubes. Hematological parameters were evaluated with a hematological analyzer Sysmex XT-2000iV according to the Sysmex manufacturer's instructions.
  • reticulocytes The most important parameter, reticulocytes (Ret), was compared between formulations and placebo. Body weight and clinical signs were also observed before and after the application and daily during experiment. At the end of experiments all animals was humanly sacrificed under C0 2 and anesthesia. Tissues and organs were macroscopically observed for potential abnormalities.
  • Recombinant human EPO - rhEPO at concentration 2.5 mg/ml (15.6 ml, 1.28 ⁇ ) was used in conjugation reactions.
  • SFB was dissolved in 100% dimethylsulfoxide (DMSO) to a concentration of 2.0 mg/ml. All reactions were performed at pH 7.0 in phosphate buffer (150 mM NaCI, 50 mM Na phosphate) using thirty fold molar excess of the N-hydroxysuccinimidyl 4-formylbenzoate (SFB) over rhEPO.
  • the concentration of DMSO in protein reaction mixture was 3.5 %. The reaction mixture was stirred slowly at 60 rpm for 16 hours at 20 °C.
  • the conjugate was separated from unreacted rhEPO, SFB and 6-aminocaproic acid by gel filtration on Superdex75 PrepGrade (XK 26/60) column. Elution (4.5 ml/min) was done with phosphate buffer (150 mM NaCI, 50 mM Na phosphate) containing 20 % glycerol. Fractions containing product were collected, concentrated and sterile filtrated. Purified EPO conjugate, mC6-EPO, was additionally analyzed by SDS-PAGE and RP-HPLC.
  • EXAMPLE 2 EXAMPLE 2:
  • Nanoparticles associating EPO or mC6EPO and cycloalkylmaltosides (CYMAL)
  • CYMAL-7® 6-cyclohexyl-1-heptyl-maltoside; 4.8 mg/ml, 0.313 ml
  • CS chitosan solution
  • tpp tripolyphosphate
  • Table 2 Composition of testing formulations of mC6EPO with CYMAL, and their formulation in chitosan nanoparticles, TEER value after 3h of treatment and 24h after the experiment (to monitor Caco-2 cells recovery), and calculated permeability for mC6EPO.
  • Enhancement ratio of P app EPO is also presented for the formulations relative to free EPO.
  • Nanoparticles containing EPO or mC6EPO and TMC as a part of the carrier material and enhancer Nanoparticles (NPs) were obtained by dropwise addition of EPO or mC6EPO (2.5 mg/ml, 0.3 ml) into the solution of chitosan and trimethylchitosan (TMC) (total polymer concentration was 4 mg/ml in 0.25% acetic acid, pH 4.8, 0.938 ml, where CS/TMC ratio was 0.5/0.5 and 0.25/0.75; and 4.6 mg/ml in 0.25% acetic acid, pH 4.8, 0.897 ml, where CS/TMC ratio was 1/0.1 ).
  • TMC trimethylchitosan
  • TEER value after 3h of treatment and 24h after the experiment (to monitor Caco-2 cells recovery), and calculated permeability for EPO.
  • Enhancement ratio of P app EPO is also presented for the formulations relative to free EPO.
  • Nanocomplexes were obtained upon dropwise addition of EPO or mC6EPO (2.5 mg/ml, 0.6 ml) using a pipette into an aqueous solution of PMAL-C10 (PMAL, [Poly(maleic anhydride-alt-1- dodecene) subsituted with 3-(Dimethylamino) propylamine], 10% stock solution suitably diluted to final concentration, see Table 4 and 5) under gentle stirring at room temperature.
  • PMAL-C10 PMAL, [Poly(maleic anhydride-alt-1- dodecene) subsituted with 3-(Dimethylamino) propylamine]
  • EPO having size about 7 nm
  • PMAL having polymodal and polydispersed distribution
  • Zeta potential (pH 7.0) of EPO, PMAL and EPO-PMAL complex were -10, -52mV and +13 mV, respectively.
  • the scattering intensity of EPO (218 kcps) and PMAL solution (216 kcps) markedly increased on their addition (EPO-PMAL 6,600 kcps) giving evidence of the complex formation.
  • Nanoparticles containing EPO-PMAL or mC6EPO-PMAL assembly were obtained further by adding the nanocomplex solution slowly into a chitosan/trimethylchitosan solution (4.8/0.96 mg/ml in 0.25% acetic acid, pH 4.8, 1.56 ml). After gentle stirring for 20 min, a tripolyphosphate (3 mg/ml, 0.449 ml) was added to form nanoparticles of uniform size distribution (particle size 200-250 nm) and low polydispersity (Pdl 0.3) measured by Zetasizer NanoZS, Malvern
  • Table 4 Composition of testing formulations of EPO-PMAL assembly and their formulation in chitosan/trimethylchitosan nanoparticles, TEER value after 3h of treatment and 24h after the experiment (to monitor Caco-2 cells recovery), and calculated permeability for EPO. Enhancement ratio of P app EPO is also presented for the formulations relative to free EPO.
  • Table 5 Composition of testing formulations of mC6EPO-PMAL assembly and their formulation in chitosan/trimethylchitosan nanoparticles, TEER value after 3h of treatment and 24h after the experiment (to monitor Caco-2 cells recovery), and calculated permeability for mC6EPO. Enhancement ratio of P app EPO is also presented for the formulations relative to free EPO. Sample Cone, (mg/ml) TEER TEER Papp EPO/ ER
  • Placebo and EPO- or mC6EPO-formulations were administered by a single gavage administration. UV sterilized Latex Free syringe with gavage needle was used for p.o.
  • Placebo and test items were administered once, i.e. on day 0.
  • Test items were prepared as freeze-dried products which were rehydrated in water before the application and prepared as a final dispersion for oral application.
  • Test item 1 labeled Lio-EPO- A contained nanoparticles composed of EPO, CYMAL7, and chitosan /tripolyphosphate. Initial loading of EPO was 2.5% and 1.5x mass excess of CYMAL7 relative to EPO was used.
  • Test item 2 labeled Lio-mC6EPO-B"' contained nanoparticles composed of mC6EPO, CYMAL7, and chitosan / tripolyphosphate with initial loading of mC6EPO 5% and 13x mass excess of CYMAL7 relative to mC6EPO. In Placebo group animals received demi water. Data evaluation
  • the most responsive hematological parameter was the number of reticulocytes determined at individual time points in the blood samples. Response curves were generated by plotting reticulocyte count against time for individual animal in each group. Individual response was evaluated by calculating AUC (area under the curve) taking zero time point (or -1 day) and day six time point as a baseline values.
  • Bioavailability (BA) from PD response of perorally administered EPO or mC6EPO formulations was calculated relative to the average AUC values obtained in the same way for subcutaneously administered EPO or mC6EPO (0.8 ⁇ g rat) using the equation:
  • Table 7 AUC values for the number of reticulocytes after subcutaneous and peroral application of different EPO or mC6EPO-formulations.
  • test item and placebo were administered by a single intrajejunal (i.j.) administration. UV sterilized Latex Free syringe with 23G needle were used for i.j. application. The test item and placebo were administered once, on day 0.
  • Rats were anaesthetized with intraperitoneal injection of a mixture of ketamine, xylazine and saline (5:4:5 v/v/v; 0.7 ml/rat, 20 % w/v solution).
  • the incision site at abdominal region was shaved and disinfected with an iodine solution.
  • the abdomen was entered through a midline incision, and the jejunum was located.
  • UV sterilized Latex Free syringe with 23G needle was introduced into the jejunum and the substance was applied.
  • the injection site was gently pressured after application to stop any leaking or bleeding.
  • the jejunum was carefully returned to its normal position within the abdominal cavity.
  • the abdominal muscles were closed with a 6-0 absorbable suture (Safile, Braun, Germany) and the abdominal skin was closed with the wound clips (Autoclip ® Wound Closing System, Braintree Scientific, USA).
  • EPO-loaded nanoparticles (NPs-EPO-D') and empty nanoparticles were administered as freshly prepared nanoparticle dispersion.
  • EPO-loaded nanoparticles labeled NPs-EPO-D'" contained nanoparticles composed of EPO, CYMAL7, and chitosan /tripolyphosphate with initial loading of EPO 15% and 13x mass excess of CYMAL7 relative to EPO.
  • Empty nanoparticles had the same composition but without the protein.
  • the most responsive hematological parameter was the number of reticulocytes determined at individual time points in the blood samples. Response curves were generated by plotting reticulocyte count against time for individual animal in each group. Individual response was evaluated by calculating AUC (area under the curve) taking zero time point and day six time point as a baseline values.
  • Bioavailability (BA) from PD response of intrajejunally administered EPO formulation was calculated relative to the average AUC values obtained in the same way for subcutaneously administered EPO (0.8 ⁇ g EPO/rat) using the equation: BAi is referred to pharmacological availability calculated from response curves of
  • Table 9 AUC values for the relative number of reticulocytes (% of erythrocytes) after subcutaneous and intrajejunal administration of EPO-formulation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions comprenant de l'érythropoïétine, un ou plusieurs amplificateurs d'absorption et/ou un ou plusieurs polymères bioadhésifs pour une administration orale.
PCT/EP2014/069183 2013-09-09 2014-09-09 Compositions d'érythropoiétine pour une administration orale Ceased WO2015032973A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13183609 2013-09-09
EP13183609.0 2013-09-09

Publications (1)

Publication Number Publication Date
WO2015032973A1 true WO2015032973A1 (fr) 2015-03-12

Family

ID=49150796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/069183 Ceased WO2015032973A1 (fr) 2013-09-09 2014-09-09 Compositions d'érythropoiétine pour une administration orale

Country Status (1)

Country Link
WO (1) WO2015032973A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020518653A (ja) * 2017-02-07 2020-06-25 マイオセプト インコーポレイティド 局所製剤及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115833A1 (en) * 2000-12-20 2002-08-22 Josef Burg Erythropoietin conjugates
US20070237827A1 (en) * 2005-01-04 2007-10-11 Hsing-Wen Sung Nanoparticles for drug delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115833A1 (en) * 2000-12-20 2002-08-22 Josef Burg Erythropoietin conjugates
US20070237827A1 (en) * 2005-01-04 2007-10-11 Hsing-Wen Sung Nanoparticles for drug delivery

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BONNIE M. GORZELLE ET AL: "Amphipols Can Support the Activity of a Membrane Enzyme", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, no. 39, October 2002 (2002-10-01), pages 11594 - 11595, XP055093761, ISSN: 0002-7863, DOI: 10.1021/ja027051b *
N. VENKATESAN ET AL: "Pharmacokinetic and pharmacodynamic studies following oral administration of erythropoietin mucoadhesive tablets to beagle dogs", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 310, no. 1-2, March 2006 (2006-03-01), pages 46 - 52, XP055093315, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2005.11.014 *
SIGNE BECK PETERSEN ET AL: "Evaluation of alkylmaltosides as intestinal permeation enhancers: Comparison between rat intestinal mucosal sheets and Caco-2 monolayers", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 47, no. 4, November 2012 (2012-11-01), pages 701 - 712, XP055093760, ISSN: 0928-0987, DOI: 10.1016/j.ejps.2012.08.010 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020518653A (ja) * 2017-02-07 2020-06-25 マイオセプト インコーポレイティド 局所製剤及び方法
US11752086B2 (en) 2017-02-07 2023-09-12 Myocept Inc. Topical formulations and methods

Similar Documents

Publication Publication Date Title
JP2980569B2 (ja) インターフェロン複合体
JP5491485B2 (ja) 薬理活性物質と粘膜粘着性高分子とが共有結合されたコンジュゲートの経粘膜投与に使用するための経粘膜投与剤
DE69521880T2 (de) Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
US20090226393A1 (en) Polymer paclitaxel conjugates and methods for treating cancer
JP2002543111A (ja) ポリマーを使用する葉酸で仲介された腫瘍細胞へのターゲッティングの増幅
WO2009152691A1 (fr) Acide gras greffé d'oligosaccharide de chitosane à modification polyglycol, procédé de préparation correspondant et utilisation dudit acide gras
KR100729015B1 (ko) Ｎ,ｏ-아미도말로네이트 백금 착화합물
TW200906440A (en) Polymers conjugated with platinum drugs
US20120213732A1 (en) Targeted delivery of antiviral compounds through hemoglobin bioconjugates
US20170100485A1 (en) Metal-polysaccharide conjugates: methods for cancer therapy
WO2024041535A1 (fr) Nanocomposition, son procédé de préparation et son utilisation
JP2004525143A (ja) 癌の治療のための化学療法剤との多糖の同時投与
WO2015032973A1 (fr) Compositions d'érythropoiétine pour une administration orale
KR20070094235A (ko) 킬레이팅 유기 고분자와 생물학적 금속으로 이루어진 나노입자, 그리고 ｅｐｒ 효과를 이용한 새로운 광범위 무독성항암제 및 그 제조 방법
WO2015032972A1 (fr) Nanoformulation de g-csf pour une administration non parentérale
US11524078B2 (en) Water-soluble macromolecular derivative of Venetoclax
JP2020537689A (ja) Ａ−ノル−５αアンドロスタン化合物を含む白血球増多製剤およびその使用
CN114276390A (zh) 一种用于抗肿瘤药物递送的二硫代氨基甲酸酯衍生物纳米药物及其制备方法与应用
WO2015032981A1 (fr) Conjugués d'érythropoïétine présentant une biodisponibilité orale
WO2020255574A1 (fr) Composition d'administration de médicament et composition pharmaceutique
JP6801908B1 (ja) ベネトクラクスの水溶性高分子誘導体
US20240398843A1 (en) Glycyrrhizin-branched polyethylene glycol conjugate for treating cancer
JPH04103538A (ja) 制癌剤副作用抑制剤
JPH09124512A (ja) 肝臓ターゲティングのための水溶性の薬物−プルラン結合体製剤
US20130259944A1 (en) Methods and compositions for treating cancer with platinum particles

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14766426

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14766426

Country of ref document: EP

Kind code of ref document: A1